RxDoctor Payments DataLook up a doctor →

Norman Friedman, MD

Neurology · Kalispell, MTNPI 1093751398

Payments from drug & device makers

$34,520in general payments, 2019–2025

Across 1,600 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$9K
  • AbbVie$5K
  • Teva Pharmaceuticals USA, Inc.$1K
  • AstraZeneca$1K
  • Supernus Pharmaceuticals, Inc.$1K
  • SK Life Science, Inc.$1K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$9,70028%
  • Speaking & faculty fees$480%
  • Travel & lodging$1,5865%
  • Food & beverage$22,75666%
  • Education$4291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Argenx US, Inc.23$8,581
AbbVie(2 entities)117$5,198
Teva Pharmaceuticals USA, Inc.153$1,371
AstraZeneca62$1,292
Supernus Pharmaceuticals, Inc.122$1,286
SK Life Science, Inc.61$1,078
EMD Serono, Inc.71$1,050
Novartis87$1,039
Amgen(2 entities)57$1,004
Biogen82$980
UCB, Inc.55$955
Lilly USA, LLC47$774
Jazz Pharmaceuticals Inc.56$736
Lundbeck LLC39$609
Harmony Biosciences LLC28$577
Genentech USA, Inc.32$570
Pfizer38$562
Biohaven Pharmaceuticals, Inc.42$547
Biohaven Pharmaceutical Holding Company Ltd.38$534
Kyowa Kirin, Inc.30$438
Axsome Therapeutics, Inc.20$372
Sanofi19$360
Eisai Inc.17$353
Greenwich Biosciences, Inc.17$336
Acadia Pharmaceuticals Inc26$333
Sunovion Pharmaceuticals Inc.30$332
Neurocrine Biosciences, Inc.19$299
Neurelis, Inc.14$233
MDD US Operations, LLC19$202
CSL Behring40$175
TG Therapeutics, Inc.9$169
Avanir Pharmaceuticals, Inc.10$168
Tanabe Pharma America, Inc.10$164
Bristol Myers Squibb9$138
Grifols USA, LLC8$133
GE HealthCare9$124
Amneal Pharmaceuticals LLC5$113
Catalyst Pharmaceuticals, Inc.6$112
Acorda Therapeutics, Inc7$103
Sumitomo Pharma America, Inc.9$96
Upsher-smith Laboratories LLC3$88
E.r. Squibb & Sons, L.L.C.5$87
Avadel CNS Pharmaceuticals, LLC3$72
Takeda Pharmaceuticals U.S.A., Inc.3$67
Impel Pharmaceuticals LLC6$64
Vanda Pharmaceuticals Inc.2$62
Inspire Medical Systems, Inc.2$57
Portola Pharmaceuticals, LLC3$49
ANI Pharmaceuticals, Inc.2$45
Xeris Pharmaceuticals, Inc.2$45
Zogenix Inc.3$45
Collegium Pharmaceutical, Inc.3$43
Sanofi-aventis U.S. LLC2$42
Avion Pharmaceuticals2$41
Octapharma USA, Inc.2$40
Johnson & Johnson3$38
Aucta Pharmaceuticals, Inc.3$23
Ipsen Biopharmaceuticals, Inc1$18
Vertical Pharmaceuticals, LLC1$16
Mallinckrodt Hospital Products Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,520 in reported general payments places this provider in the 80th percentile of 48 neurology providers in Montana.

See all neurology providers in Montana

Medicare billing

Part B allowed, 2024
$793,016
Medicare patients
225
Services billed
51,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab19$651,609
AustedoDeutetrabenazine13$55,000
Nurtec OdtRimegepant Sulfate30$35,704
XcopriCenobamate22$25,350
Emgality PenGalcanezumab-Gnlm11$15,180
Levetiracetam247$10,600
Ajovy AutoinjectorFremanezumab-Vfrm12$8,803
DilantinPhenytoin Sodium Extended16$6,988
Carbamazepine104$6,480
Carbidopa-LevodopaCarbidopa/Levodopa151$4,887
Gabapentin160$3,613
Divalproex Sodium ErDivalproex Sodium54$3,081
Mycophenolate Mofetil32$2,969
Entacapone16$2,775
Primidone65$2,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$1,292$651,60919 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,371$55,00013 claims
PfizerNurtec Odt, Dilantin$562$42,69146 claims
SK Life Science, Inc.Xcopri$1,078$25,35022 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$113$3,72044 claims
Upsher-smith Laboratories LLCTopiramate$88$95079 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 48 neurology providers in Montana.

Other neurology in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →